Background: Attempts to reduce the burden of vascular disease in advanced chronic kidney disease (CKD) by control of lipids have not been as successful as predicted. Aim: To determine the extent to which the effectiveness of statins varies by kidney class. Design: Meta-analysis. Methods: We selected randomized trials of statin vs. placebo that gave outcomes for CKD3 (eGFR 30-59 ml/min), CKD4 (eGFR 15-29 ml/min), CKD5 (eGFR < 15 ml/min)/5D(dialysis) and transplant patients separately. Data sources were the Cholesterol Triallists' Treatment Collaboration and previously published meta-analyses. Main outcome measures were major cardiovascular events (MACE), cardiovascular death and all-cause mortality (ACM). Results: A total of 13 studies provided 19 386 participants with CKD3, 2565 with CKD4, 7051 with CKD5/5D and 2102 with a functioning renal transplant. Statins reduced MACE (pooled HR 0.72, 95% CI 0.67-0.78) and ACM (0.82, 0.73-0.91) in CKD3; probably reduced MACE (0.78, 0.62-0.99) in CKD4; and probably reduced cardiovascular death (0.62, 0.40-0.96) in renal transplants. There were no cardiovascular or ACM data in CKD4; there was no convincing evidence of benefit for any outcome in CKD5/5D; and no significant reduction in MACE or ACM in patients with a functioning transplant. Conclusions: Statins are indicated in CKD3, probably indicated in CKD4, not indicated in CKD5/5D and probably indicated in patients with a functioning transplant. Too few patients with CKD4 and renal transplants have been included in lipid lowering trials for confident conclusions to be drawn.
Introduction
People with chronic kidney disease (CKD) carry a high risk of vascular disease and are much more likely to die from vascular causes than those who do not have CKD. 1 The risk of vascular death increases with the severity of CKD and may be between 8 and 10 times greater than that of the general population by the time a patient starts dialysis. 2 It is disappointing therefore that attempts to reduce the burden of vascular disease in advanced CKD by control of lipids have not been as successful as predicted, [3] [4] [5] [6] contradicting the widely held view that patients at higher risk of disease generally benefit more from treatment. Eight meta-analyses of lipid lowering in renal disease have been published. The most recent and largest of these, the Cholesterol Triallists Treatment Collaboration, chose not to present data for patients with CKD4 or with renal transplants separately. 7 Palmer et al. 8 considered all patients from those microalbuminuria to CKD5 as one group then compared outcomes with patients on dialysis and patients with transplant. Both Upadhyay et al. 9 and Su et al. 10 pooled outcomes for all patients from microalbuminuria to transplant. Hou et al. 11 combined CKD2
and CKD3 before comparing outcomes with a combined group of CKD4 and CKD5/5D. Green et al. 12 limited their analysis to dialysis patients only while Major et al. limited theirs to patients with CKD3 and no prior coronary heart disease (CHD). 13 The metaanalysis by Yan et al. 14 was primarily a comparison of more vs. less statin. With one exception 8 the authors of the meta-analyses comparing statins with placebo felt their findings supported the widespread use of statins in patients with CKD. Yan et al. 14 concluded that the benefits of high intensity statin therapy were unclear. We chose not to replicate these studies for two reasons: first, we did not wish to include patients with microalbuminuria and CKD2 as this would have meant assessing all trials of statins in older adults which was not our primary objective; and second, we felt that pooling patients with different severity of CKD would assume that all patients with CKD behave similarly irrespective of stage. We do not believe that this is the case. Indeed it would appear that statins are more effective in CKD3 than in patients on dialysis. 15 We suspect this is a consequence of a change in the nature of the vascular disease in kidney patients from primarily atherosclerotic to predominantly calcific pathology with myocardial fibrosis an important contributory factor. 1 If true this might be a reason why statins lose their benefit as renal failure progresses. Against this background the aim of our meta-analysis was to quantify the benefits of statin therapy at different stages of CKD and to determine the point at which statins become less effective by examining, where possible, patients with CKD3 (eGFR 30-59 ml/ min), CKD4 (eGFR 15-29 ml/min), CKD5 (eGFR < 15 ml/min)/5D (patients on dialysis) and those with renal transplant separately.
Materials and methods
We selected studies by checking the reference lists of previous systematic reviews in order to avoid duplicating the work of others. Sources of studies about the effect of statins in patients with CKD were the Cholesterol Treatment Triallists Collaboration, 7 the meta-analyses by Palmer et al., 8 Upadhyay et al., 9 Su et al., 10 Hou et al., 11 Green et al., 12 Major et al. 13 and Yan et al., 14 and the Cochrane Review by Taylor et al.
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From these reports we included randomized trials of statin vs. placebo that gave outcomes for CKD3, CKD4, CKD5, dialysis (CKD5D) or transplant patients separately in their main results articles, in CKD substudies or in pooled analyses. Four trials were conducted exclusively in subjects with CKD, [3] [4] [5] [6] eight were CKD substudies of primary or secondary prevention trials [17] [18] [19] [20] [21] [22] [23] [24] and one was a pooled analysis of WOSCOPS, CARE and LIPID. 25 We excluded studies with fewer than 300 patients, trials of more vs. less statin but no placebo group, 26-28 trials of less than one year's duration 29 and an open label extension to ALERT that increased average follow up from 5.1 to 6.7 years for patients randomized to fluvastatin. 30 We independently extracted data for the following three outcomes: major cardiovascular events (MACE), cardiovascular death and all-cause mortality (ACM); and for the following five categories of CKD: CKD3, CKD4, CKD5, dialysis (CKD5D) and renal transplant. The definitions of MACE and cardiovascular death varied, as shown in Appendix 1.
We obtained hazard ratios and CIs from each article and derived variances of the log hazard ratios from the reported CIs. For the LIPS substudy, 23 log hazard ratio and variance were derived from the numbers at risk and numbers of events per year given in the article, using the method suggested by Parmar et al. 31 We weighted results by the inverse of the variance of the log hazard ratio and derived pooled effects within each CKD group by fitting a meta regression model predicting log hazard ratio from CKD class. We used mixed effect models to account for heterogeneity of the studies. 
Patient involvement
No patients were involved in setting the research question or the outcome measures, nor were patients involved in the design and implementation of the study. There are no plans to involve patients in disseminating the results.
Results Table 1 shows the characteristics of the 13 studies in our metaanalysis. A total of 17 263 participants in 8 primary or secondary prevention trials and 1 pooled analysis had CKD3. One trial had a mixed population of both dialysis and non-dialysis patients including 2111 with CKD3, 2565 with CKD4, 1221 with CKD5 and 3023 with CKD5D. Two trials were conducted exclusively in patients on dialysis contributing 4028 to a total of 8272 CKD5/5D patients for the meta-analysis. One trial with 2102 participants was undertaken in patients with a functioning renal transplant. Study duration varied from 1.9 to 5.5 years. Baseline estimated GFR was as reported in the original papers. All included trials were placebo controlled. Six different statins were assessed: pravastatin in three trials, atorvastatin, rosuvastatin, simvastatin and fluvastatin in two trials each, lovastatin in one trial. One trial tested a combination of SHARP main results paper implies that baseline LDL was 2.9mmol/l for all non-dialysis patients. 2 Data for all 4S patients with eGFR <75ml/min as LDL levels for those with eGFR 30-59ml/min not given separately. 3 Data for all HPS trial participants as LDL levels in renal subgroup not given separately.
simvastatin and ezetimibe. The statin dose, absolute and percentage LDL reduction and achieved LDL in each trial are as shown. There is a suggestion here that absolute LDL reduction was less in the trials of patients with more advanced renal failure. All 13 studies reported MACE, 4 reported cardiovascular mortality while 9 reported ACM. The total number of events available for meta-analysis were 5406, 1183 and 3518 for MACE, cardiovascular death and ACM, respectively. The number of events with hazard ratios and CIs for each end point are given by trial in Table 2 and by CKD class in Figure 1 . For MACE, we found a significant protective treatment effect for CKD3 (HR 0.72, 95% CI 0.67-0.78, P < 0.001) and CKD4 (HR 0.78, 95% CI 0.61-0.99, P ¼ 0.041), but not for CKD5/5D (HR 0.92, 95% CI 0.84-1.02, P ¼ 0.099) or transplant patients (HR 0.83, 95% CI 0.64-1.08, P ¼ 0.161). The treatment effect in CKD3 was significantly stronger than for CKD5/5D (P ¼ 0.001), other pairwise comparisons were not significant. Residual heterogeneity of the model was low (I 2 ¼ 8.06%, P ¼ 0.235). In the sensitivity analysis for MACE, study type was not significant (P ¼ 0.723). For ACM, we found again that the treatment effect was strongest in CKD3 (HR 0.82, 95% CI 0.73-0.91, P ¼ 0.001) with no significant benefit in CKD5/5D (HR 0.95, 95% CI 0.87-1.04, P ¼ 0.262) or transplant patients (HR 1.02, 95% CI 0.81-1.29, P ¼ 0.870). The treatment effect was stronger in CKD3 than in CKD5/5D (P ¼ 0.040), otherwise pairwise comparisons were not significant. There were no ACM data for CKD4. Residual heterogeneity of the model was low (I 2 ¼ 0.00%, P ¼ 0.291).
For cardiovascular mortality, we noted a significant treatment effect in transplant patients (HR 0.62, 95% CI 0.40-0.96, P ¼ 0.031) but no significant benefit for CKD3 (HR 0.75, 95% CI 0.52-1.09, P ¼ 0.130) or CKD5/5D (HR 0.92, 95% CI 0.75-1.12, P ¼ 0.409). Pairwise comparisons were not significant. There were no cardiovascular mortality data for CKD4. There was residual heterogeneity (I 2 52.64%), but homogeneity was not rejected (P ¼ 0.146). There were 9674 subjects with CKD3 in five primary prevention trials and 9712 subjects with CKD3 in five trials that included a significant proportion of subjects with prior CHD (Table 1) . Splitting CKD3 into those with and without prior CHD and repeating the analyses for MACE and ACM (none of the primary prevention trials reported cardiovascular mortality), we found that the benefits of statins were not simply confined to CKD3 participants with CHD. Hazard ratios for MACE were 0.75 (95% CI 0.70-0.81, P < 0.001) for those with and 0.60 (95% CI 0.50-0.72, P < 0.001) for those without prior CHD. The treatment effect in CKD3 without prior CHD was significantly stronger than for CKD3 with prior CHD (P ¼ 0.023). Residual heterogeneity of the model was low (I 2 ¼ 0.00%, P ¼ 0.533).
Corresponding hazard ratios for ACM in CKD3 were 0.86 (95% CI 0.76-0.97, P ¼ 0.013) for those with and 0.62 (95% CI 0.46-0.822, P ¼ 0.001) for those without prior CHD. Again, there was a significant difference in the treatment effects between CKD3 with and without prior CHD, favouring those without CHD (P ¼ 0.036). Residual heterogeneity of the model was low (I 2 ¼ 0.03%, P ¼ 0.712). There was no difference in treatment effects for MACE when we split CKD 5/5D into trials that included or did not include patients with prior CHD (analysis not possible for ACM or cardiovascular mortality), though we recognize this could also be due to low numbers of events in subgroups.
Discussion
The authors of SHARP, the largest of the lipid lowering trials in patients with CKD, interpreted the results of that trial as supporting the widespread use of statins in both dialysis and nondialysis patients. 6 That view has since been challenged by the consistent failure of lipid lowering studies to benefit dialysis patients, leading KDIGO in 2014 to recommend treatment with statin or statin/ezetimibe combination in adults aged !50 years with eGFR <60 ml/min but not treated with renal replacement therapy or renal transplant. 15 There is an assumption here that all predialysis patients will benefit and it is possibly for this reason that none of the recent guidelines distinguish between CKD3, CKD4 and CKD5. The Joint British Societies 3 Guideline suggests that lipid lowering therapy with statins be considered in all adults with stages 3-5 CKD, 35 while NICE advise atorvastatin 20 mg daily for the primary or secondary prevention of CVD for all people with CKD (which they define as eGFR <60 ml/min and/or urine ACR > 3 mg/mmol). 36 Five of the eight CKD meta-analyses came to essentially the same conclusion, namely that statins be considered for cardiovascular disease prevention in most patients with CKD. [9] [10] [11] [12] [13] The CTTC observed a trend towards smaller reduction in major vascular events as eGFR declined but did not advise against treating patients with advanced renal failure, concluding instead that statin based regimens should be chosen to maximize the absolute reduction in LDL cholesterol to achieve the largest treatment benefit. 7 Pooling patients with CKD3, 4 and 5 seems illogical to us for two reasons: first, CKD3 occurs in up to one-third of UK adults over 75 years of age and is around 20Â more common than CKD4 and 5 37 ; and second, pooling takes no account of the change in pathophysiology of the vascular disease from atherosclerotic to calcific arteriopathy and myocardial fibrosis as renal failure progresses. 1 The other meta-analyses 7-14 did not address this question directly and it was for this reason that we undertook our own. The main findings of our meta-analysis were as follows. We found a convincing benefit of statins for MACE and ACM in CKD3 especially in patients without prior CHD but also in those with prior CHD. Reduction of cardiovascular mortality in CKD3 is not significant, but the estimated HR is of similar magnitude. In CKD4, statins reduce MACE significantly but for ACM and cardiovascular mortality there are no data. In CKD5/5D, estimated treatment effects are small and not significant for any of the endpoints. In transplant patients the results do not suggest a treatment effect on ACM or MACE. For cardiovascular mortality, there appears to be a protective effect which just achieves statistical significance. We are aware that an open label extension to ALERT has suggested a likely benefit for MACE but since both groups received statins in the extension period we did not feel that those results could be incorporated in the meta-analysis. 30 There are several possible explanations why statins become less effective at reducing vascular events as renal function declines. First, the changes in pathophysiology described above may lead to death from heart failure and arrhythmia rather than myocardial infarction. 1 We would not expect lipidlowering therapy to benefit either of these conditions. Second, dialysis patients have additional uremia-related risk factors that include anaemia, hyperphosphatemia, oxidative stress, inflammation and accumulation of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine, which results in reduced nitric oxide synthesis and may significantly contribute to CVD. 1 Again, none of these factors are likely to be improved by lipid lowering therapy. Third, it is possible that failure to demonstrate benefit with statins in patients with more severe kidney disease reflects lower baseline LDL cholesterol and smaller absolute reductions in LDL cholesterol as eGFR declines. 7 However, the CTTC adjusted for these possibilities by reporting event rates per mmol of LDL reduction and showed that the relative reduction in major vascular events observed with statin-based treatment does indeed become smaller as renal failure progresses.
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Our meta-analysis did not directly address the question whether benefit in CKD3 reflected statin responsive atherosclerotic disease and that failure to benefit in CKD5/5D was a consequence of calcific arteriopathy/myocardial fibrosis, though this may be inferred from a comparison of outcomes in WOSCOPS 38 and SHARP. 6 WOSCOPS was a primary prevention trial of middle aged men with essentially normal renal function whereas SHARP was a trial of men and women, 27% of whom had CKD3 and 73% CKD4 þ CKD5/5D. Average follow-up in both trials was 4.9 years. ACM in SHARP participants randomized to placebo was 6Â that of the WOSCOPS placebo group, yet the proportion of participants who died a CHD death in the placebo groups of SHARP and WOSCOPS was identical (Figure 2 ). CHD deaths were responsible for only 7.9% of SHARP deaths but for 46.3% of WOSCOPS deaths. If statins were only able to reduce the incidence of CHD deaths in both trials then it is perhaps unsurprising that statins appeared less effective in SHARP than in WOSCOPS. We acknowledge limitations. In our comparison of statin trials it was not always possible to compare like with like as definitions of MACE and cardiovascular death differed. Some of these differences were minor and some not (Appendix 1). AURORA included fatal stroke in their cardiovascular deaths 5 whereas 4D
did not. 4 Cardiovascular deaths in ALERT were cardiac deaths only. 3 In each of these examples the choice of endpoint may have inadvertently influenced the result of the trial in question: respectively more fatal strokes and non-cardiac vascular deaths occurred in 4D and ALERT patients who were randomized to statin therapy. There is, moreover, no agreed method for determining the precise cause of vascular death in patients with advanced CKD, an issue that has recently been addressed, though not completely resolved, by the CTTC meta-analysis. 7 We also recognize that we did not attempt to analyse outcomes other than MACE, vascular death and ACM. Others have done so and have found no increase in risk of adverse events 16 with the possible exception of type 2 diabetes. 39 We accept that our analysis sheds no light on the question whether statins started in CKD3 should be stopped if and when a patient reaches stage 5/5D. The trials were of patients starting statins in different stages of CKD and didn't include patients already on statins. We further acknowledge that we relied on local expertise, previously published meta-analyses and systematic reviews rather than duplicate the work of others by conducting a formal literature search. As a direct consequence of this approach, however, we were able to incorporate data from PROSPER that were not included in several other metaanalyses, [8] [9] [10] [11] 13 allowing us to analyse results from no fewer than 19386 subjects with CKD3. We are confident that this strategy has yielded all relevant studies up to and including those published by 11 May 2016 and that risk of bias in included trials was low. 7 Based on our meta-analysis and on our interpretation of the literature we believe that statins are indicated in CKD3, probably indicated in CKD4, not indicated in CKD5/5D and probably indicated in patients with a functioning transplant. We do not feel the available evidence currently supports the more widespread use of statins in CKD that has been recommended by some authorities 9, 11, 13, 35, 36 simply because the trials and metaanalyses on which their recommendations are based have not yet included large enough numbers of patients with CKD4 and functioning renal transplants for confident conclusions to be drawn.
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